BackNatureWise Biotech & Medicals Overview

NatureWise Biotech & Medicals Other Current Assets

Latest other current assets for 4732.TWO: $35M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$35.30M
↑ 165.04% YoYΔ $21.98M vs prior year quarter

Peer average / median

Loading

NatureWise Biotech & Medicals Other Current Assets History

Loading

NatureWise Biotech & Medicals vs. peers: Other Current Assets Comparison

Loading

NatureWise Biotech & Medicals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NatureWise Biotech & Medicals (4732.TWO) FAQ

NatureWise Biotech & Medicals's other current assets stands at $35M as of June 2026. That compares with $13M in the prior-year period — up 165.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NatureWise Biotech & Medicals reported $35M in other current assets versus $13M a year earlier — a 165.0% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $13M in the prior-year period — up 165.0% year over year. Sustained growth in other current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how NatureWise Biotech & Medicals's other current assets evolved across reporting periods, while the comparison chart places 4732.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current assets is commonly used to spot outliers. NatureWise Biotech & Medicals's reading of $35M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.